Clinical Study

H3b-6527-G000-101- An Open-Label Multicenter Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of H3b-6527 In Subjects With Advanced Hepatocellular Carcinoma Or Intrahepatic Cholangiocarcinoma

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine the maximum tolerated dose of H3B-6527 in subjects with advanced liver cancer and assess the safety and tolerability of H3B-6527 as a single agent administered orally


To Be Eligible: Must Have Advanced Liver Cancer, Age 18 Or Older, Fgf19+, Nonpregnant/Breastfeeding, No Other Malignancy Or Infection


Hepatocellular Carcinoma, Cancer, Liver Cancer, Liver, Phase I

For More Information:

Uc Cancer Institute
(513) 584-7698

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.